7/31/2019 CLINICAL RELEVANCE OF ADALIMUMAB SERUM CONCENTRATION AND ANTI-ADALIMUMAB ANTIBODIES IN PATIENTS

1/2

Abstract View

Monday, October 22, 2012

Type: Poster Session

Session title: IBD I

Time: 09.00-17.00

Room: Hall 1

P0296

CLINICAL RELEVANCE OF ADALIMUMAB SERUM CONCENTRATION

AND ANTI-ADALIMUMAB ANTIBODIES IN PATIENTS WITH CROHN

DISEASE DURING LONG-TERM FOLLOW-UP

Giorgia Bodini Poster Presenter

Vincenzo Savarino Co-Author

Lorenzo Gemignani Co-Author

Valentina Fazio Co-Author

Elisa Giambruno Co-Author

Pietro Dulbecco Co-Author

Edoardo Savarino Co-Author

INTRODUCTION/OBJECTIVES:

Trough serum levels of Adalimumab (ADA) and anti-ADA antibodies have been associated to loss ofresponse in patients with inflammatory-related diseases. However, little is known regarding the clinical

influence of these features in patients with Crohns disease (CD) during long-term follow-up.

AIMS & METHODS:To evaluate the course of ADA serum concentration and anti-ADA antibodies formation and their clinicalrelevance during a long-term (2 year) follow-up period of patients with CD. In this prospective study, 22

consecutive infliximab-nave patients (13M/9F) with CD, who achieved remission and in maintenance

treatment with ADA, were included in a follow-up program. Blood samples were drawn at standardizedtime points (i.e. at 6, 12, 18, 24 months and in case of CD relapse) just before injection of ADA. TroughADA serum concentration and anti-ADA antibodies were measured using an enzyme-linked

immunosorbent assays (Matriks biotek). Disease activity was assessed at the same points by means of the

Harvey-Bradshaw Index score (HBI, remission 16) and CRP blood level (normal if

7/31/2019 CLINICAL RELEVANCE OF ADALIMUMAB SERUM CONCENTRATION AND ANTI-ADALIMUMAB ANTIBODIES IN PATIENTS

2/2

Patients with CD classified by means of HBI

RemissionMild

DiseaseModerateDisease

SevereDisease

n=10 n=3 n=6 n=3

Parametersp Value(Anova)

HBI score, n 4 (3-4) 6 (5-7) 9 (8-11) 17 (16-17)